Phio Pharmaceuticals reported Q3 2024 financial results with a net loss of $1.5 million, down from $2.8 million YoY. Cash position stood at $5.4 million as of September 30, 2024. The company raised approximately $2.6 million through warrant exercises in July 2024. Research and development expenses decreased 64% to $0.6 million, while general and administrative expenses slightly decreased to $0.95 million.The Phase 1b clinical trial for PH-762 showed promising results, with one patient achieving complete response (100% tumor clearance) and another showing partial response (90% tumor clearance) in the second cohort. The trial received positive safety recommendations to advance to the next dose level, with the third cohort screening set to begin December 10, 2024. A sixth clinical trial site was added in San Diego.The company presented new data on its INTASYL technology at multiple conferences, including the CAR-TCR Summit and SITC annual meeting. A peer-reviewed article highlighting the INTASYL compound PH-804 was published in Cancer Immunology, Immunotherapy, demonstrating enhanced NK cell cytotoxicity against cancer.

Phio Pharmaceuticals reported Q3 2024 financial results with a net loss of $1.5 million, down from $2.8 million YoY. Cash position stood at $5.4 million as of September 30, 2024. The company raised approximately $2.6 million through warrant exercises in July 2024. Research and development expenses decreased 64% to $0.6 million, while general and administrative expenses slightly decreased to $0.95 million.The Phase 1b clinical trial for PH-762 showed promising results, with one patient achieving complete response (100% tumor clearance) and another showing partial response (90% tumor clearance) in the second cohort. The trial received positive safety recommendations to advance to the next dose level, with the third cohort screening set to begin December 10, 2024. A sixth clinical trial site was added in San Diego.The company presented new data on its INTASYL technology at multiple conferences, including the CAR-TCR Summit and SITC annual meeting. A peer-reviewed article highlighting the INTASYL compound PH-804 was published in Cancer Immunology, Immunotherapy, demonstrating enhanced NK cell cytotoxicity against cancer.